In December 2025, FDA warned that counterfeit Ozempic injection 1 mg had been found in the legitimate U.S. drug supply chain. FDA said it was notified by Novo Nordisk in November 2025, that the agency’s investigation was ongoing, and that retail pharmacies, wholesalers, health care professionals, and patients should closely inspect products for signs of counterfeit labeling. FDA also warned that counterfeit needles associated with the product raised sterility concerns, creating the possibility of infection.
That is an important pharmacy-error story because it shifts attention to a form of medication danger that patients do not always think about. Many people hear “pharmacy mistake” and think of the wrong bottle or the wrong instructions. Those cases matter, but medication safety failures can also involve sourcing, verification, packaging review, and the breakdown of safeguards that are supposed to stop suspect products before they reach a patient.
This issue is especially significant because Ozempic is a widely recognized medication, and a patient receiving a counterfeit version may have no obvious reason to doubt what they were handed. FDA’s broader guidance on counterfeit medicine explains that counterfeit drugs may contain the wrong ingredients, too much or too little active ingredient, no active ingredient at all, or other harmful ingredients.
A Pharmacy Case Is Not Limited to the Wrong Prescription
A pharmacy negligence discussion should be broad enough to match how harm actually occurs. In a case involving a counterfeit or compromised medication, the key questions may include how the product entered circulation, what warning signs existed, what inspection steps were required, and whether the dispensing pharmacy had procedures that could have identified the problem before the medication reached the patient.
That does not mean every counterfeit-drug incident automatically becomes a viable negligence claim against a retail pharmacy. It does mean the pharmacy’s role should not be ignored. If pharmacies are part of the final checkpoint before a medication reaches a patient, their safety systems matter.
Why This Matters for People in Maryland and Washington, D.C.
People picking up medication in Maryland or D.C. usually assume the most basic thing of all: that the medication is authentic and safe to use as labeled. A counterfeit-drug incident disrupts that trust in a profound way. It also creates a more complicated injury picture than a classic misfill case because the problem may involve multiple points in the chain, from distribution to handling to final dispensing.
The practical lesson is simple. Medication harm is not always obvious at the counter. When a patient is injured after receiving a suspect drug, the investigation may need to examine sourcing records, lot information, packaging, pharmacy protocols, and the timing of FDA or manufacturer notices.
Contact Lebowitz & Mzhen if a Medication Error Caused Harm
Lebowitz & Mzhen Personal Injury Lawyers understands that pharmacy injury cases can leave people feeling blindsided. You trust the medication in your hand because the system is supposed to protect you long before it reaches the pharmacy counter. When that protection breaks down, the firm focuses on how the failure happened, what safeguards were missed, and what the injury has cost the patient and family. That kind of advocacy matters in cases where the mistake may be hidden inside a chain of handling and distribution.
If you were injured by a dispensing problem, labeling issue, counterfeit medication concern, or another serious pharmacy-related mistake in Maryland or Washington, D.C., Lebowitz & Mzhen Personal Injury Lawyers offers free consultations. Call (800) 654-1949 or send a message through the online contact form to discuss your situation.